Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma

Clin Immunol. 2022 Dec:245:109178. doi: 10.1016/j.clim.2022.109178. Epub 2022 Nov 8.

Abstract

Immune checkpoint (IC) therapy has led to a breakthrough in cancer treatment. However, the interaction of ICs is controversial in glioma. We detected features of ICs using transcriptome data and a multicolor immunofluorescence assay. We discovered that B7-H3 increased with grade and age and predicted worse overall survival (OS) at the transcriptional and proteomic levels. VISTA and PD-L1 were associated with OS and grade at the RNA level. At the protein level, VISTA was primarily expressed in tumor cells and TAMs. B7-H3 and VISTA were positively correlated with PD-L1. There was a strong correlation between PD-L1 and CD3 and between VISTA and IBA-1. PD-L1 was coexpressed with T cells. VISTA was coexpressed with TAMs. In T cells, we found a strong correlation in ICs, which worsened in TAMs and tumor cells. In conclusion, B7-H3 is a vital prognostic target for immunotherapy. We provided a potential mechanism for the immunosuppressive microenvironment in glioma.

Keywords: B7-H3; Glioma; PD-L1; VISTA; mIF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7 Antigens / genetics
  • B7 Antigens / metabolism
  • B7-H1 Antigen*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Glioma* / genetics
  • Humans
  • Proteomics
  • Tumor Microenvironment

Substances

  • B7-H1 Antigen
  • B7 Antigens
  • Biomarkers, Tumor